IP Library Granted Patent US 10,190,104
Granted Patent B2
US 10,190,104 · App. 15/288,531 · Granted Jan 29, 2019

Isoform of anaplastic lymphoma kinase and its uses

Inventors: Ping Chi (New York, NY); Thomas Wiesner (New York, NY); Yu Chen (New York, NY)
Assignee: Memorial Sloan Kettering Cancer Center
C12N9/12A61K31/4545A61K31/506A61K31/5377A61K31/545C12Q1/6886C12Y207/10G01N33/57484C12Q2600/106C12Q2600/158G01N2333/912G01N2500/10G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,190,104
App. No.
15/288,531
Granted
Jan 29, 2019
Kind
B2
Abstract

The present invention relates to a Truncated isoform of Anaplastic Lymphoma Kinase (“TALK”). Expression of this isoform is associated with malignancy and with responsiveness to ALK inhibitors. Detection of the isoform may be used in diagnostic and therapeutic methods. Because it arises as a result of variant transcription rather than genetic rearrangement, its presence would be undetected by genomic testing.

Claims (10)

1. An isolated complementary DNA (cDNA) molecule comprising the nucleic acid sequence of exons 20-29 and a portion of intron 19 of an Anaplastic Lymphoma Kinase (ALK) gene, wherein the cDNA molecule does not comprise the nucleic acid sequence of exons 1-19 of the ALK gene, either individually or in any combination and wherein the portion of intron 19 of the ALK gene is about 400 bp in length located upstream of exon 20 of the ALK gene.

2. The isolated cDNA molecule of claim 1 , wherein the ALK gene is a human ALK gene.

3. The isolated cDNA molecule of claim 1 , comprising:

(a) nucleic acids 405-2063 of the nucleotide sequence set forth in SEQ ID NO: 11;

(b) nucleic acids 411-2063 of the nucleotide sequence set forth in SEQ ID NO: 11; or

(c) nucleic acids 465-2063 of the nucleotide sequence set forth in SEQ ID NO: 11.

4. The isolated cDNA acid molecule of claim 1 , wherein the cDNA molecule consists essentially of SEQ ID NO: 11.

5. A vector comprising the isolated nucleic acid molecule of claim 1 .

6. A vector comprising the isolated cDNA molecule of claim 4 .

7. A host cell comprising the vector of claim 5 or 6 .

Assignments (2)
CONFIRMATORY LICENSE Recorded Oct 30, 2017
From: SLOAN-KETTERING INST CAN RESEARCH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044634/0390 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2017
From: CHI, PING; WIESNER, THOMAS; CHEN, YU
To: MEMORIAL SLOAN-KETTERING CANCER CENTER
Reel/Frame 041338/0977 →
Continuity (3)
Continuation PCTUS2015025289 · Apr 10, 2015
Provisional Application 61978106 · Apr 10, 2014
Related Publication 20170022485A1 · Jan 26, 2017